Brain Navi Biotechnology

Brain Navi operates in the medical-device and surgical-robotics intersection, with a specific focus on neurosurgical navigation rather than broad-purpose hospital robotics. Its NaoTrac system combines machine vision, AI, robotics and 3D CT/MRI imaging to support patient registration, surgical planning and instrument positioning. The SMART surface-mapping and auto-registration approach is a stated differentiator: it is designed to reduce reliance on physical tracking connections to stationary equipment while keeping surgeons involved in the procedure. KrystoLens extends the portfolio into single-use 3D neuro-endoscopy. The competitive field includes established medical-technology and surgical-robotics names such as Brainlab, Medtronic, Globus Medical, Renishaw, Zimmer Biomet, Accuray and Monteris Medical, which have been identified among companies active in the broader robotic-neurosurgery market. Brain Navi’s profile is more specialized, centering on image-guided cranial procedures and an autonomous navigation workflow. Its reported first Spanish surgeries in August 2025 and commercial launch announcement in May 2026 offer evidence of deployment beyond product development.

Brain Navi’s development path has moved from early financing toward product deployment and international market access. Its recorded Seed round was announced on December 31, 2017, with Sunsino Ventures Group as lead investor. On September 17, 2020, 500 Kobe led a non-equity assistance round. The product portfolio now includes NaoTrac, a robotic neurosurgical navigation system, and KrystoLens, a single-use 3D neuro-endoscope; an associated educational training offering is also listed. The key operational inflection point was NaoTrac’s reported first surgeries in Spain on August 7, 2025, followed by a May 26, 2026 announcement describing the robot as brought to market. Distribution and commercialization announcements involving Medtreq Medical Equipment, Palex Healthcare and BenQ Medical Technology indicate an expansion model reliant on regional partners. Overall, the evidence supports a shift from product development into clinical use and cross-border commercialization, while the pace and durability of growth cannot be judged without disclosed sales, deployment counts, regulatory milestones or updated financing data.